

Please Direct All Correspondence to Customer Number **20995**

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Matti Sällberg
App. No : 10/773,628
Filed : February 5, 2004
For : GLYCOSYLATED SPECIFICITY
EXCHANGERS
Examiner : Louise Wang Zhiying Humphrey
Art Unit : 1648

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 4, 2006

(Date)

Eric S. Furman, Ph.D., Reg. No. 45,664

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450


Alexandria, VA 22313-1450


Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
- (X) Listing 6 references.
 - (X) Enclosing 6 references.
- (X) A check in the amount of \$180 to cover the above fee is enclosed.
- (X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.


Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT


Applicant : Matti Sällberg
App. No : 10/773,628
Filed : February 5, 2004
For : GLYCOSYLATED SPECIFICITY
EXCHANGERS
Examiner : Louise Wang Zhiying Humphrey
Art Unit : 1648

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 4, 2006

(Date)


Eric S. Furman, Ph.D., Reg. No. 45,664

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing six references to be considered by the Examiner. Also enclosed are six foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 4, 2006

By: 
Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

12/08/2006 CHEGA1 00000039 10773628

01 FC:1006

100.00 OP



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/773,628
Filing Date	February 5, 2004
First Named Inventor	Matti Sällberg
Art Unit	1648
Examiner	Louise Wang Zhiying Humphrey
Attorney Docket No.	TRIPEP.056A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	1	JP 04347162A	12-2002			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	2	Bour et al., The Human Immunodeficiency Virus Type 1 CD4 Receptor and its Central Role in Promotion of HIV-1 Infection, Microbiological Reviews, Mr. 1995, Vol. 59, No. 1, p. 63-93	
	3	Communication Pursuant to Article 96(2) EPC dated July 5, 2006, from European Patent Application No. 04 708 416.5	
	4	Lanza et al., "Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain. Proceedings of the National Academy of Sciences of the United States of America (Washington, DC), December 1993, Vol. 90, pp. 11683-11687	
	5	Luning et al., "Solid Phase Synthesis of the Fibronectin Glycopeptide V(Gal beta 3GalNAc alpha)THPGY, its Beta Analogue, and the Corresponding Unglycosylated Peptide," Glycoconjugate Journal, 1991 Dec, Vol. 8(6), pp. 450-455	
	6	Seitz et al., Glycopeptide synthesis and the effects of glycosylation on protein structure and activity, Chembiochem 2000, Vol. 1, pp. 214-246	

3163581
113006

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.